Positive News SentimentPositive NewsNASDAQ:OPRX OptimizeRx (OPRX) Stock Forecast, Price & News $14.93 +0.02 (+0.13%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$14.70▼$15.1050-Day Range$11.63▼$15.6352-Week Range$11.59▼$30.82Volume90,641 shsAverage Volume209,095 shsMarket Capitalization$255.75 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media OptimizeRx MarketRank™ ForecastAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside39.9% Upside$21.00 Price TargetShort InterestHealthy4.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.81) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsComputer And Technology Sector166th out of 594 stocksBusiness Services, Not Elsewhere Classified Industry35th out of 90 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, OptimizeRx has a forecasted upside of 39.9% from its current price of $15.01.Amount of Analyst CoverageOptimizeRx has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.34% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OptimizeRx has recently decreased by 19.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.1 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 1 news article for OptimizeRx this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions80.45% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.81) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -19.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OptimizeRx (NASDAQ:OPRX) StockOptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.Read More Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesMay 30, 2023 | americanbankingnews.comQ1 2024 EPS Estimates for OptimizeRx Co. Increased by Analyst (NASDAQ:OPRX)May 28, 2023 | americanbankingnews.comAnalysts Set OptimizeRx Co. (NASDAQ:OPRX) Target Price at $19.20June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 26, 2023 | americanbankingnews.comSVB Leerink Equities Analysts Increase Earnings Estimates for OptimizeRx Co. (NASDAQ:OPRX)May 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: OptimizeRx (OPRX) and UiPath (PATH)May 25, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on OptimizeRx (OPRX)May 24, 2023 | finance.yahoo.comOptimizeRx’s CEO Provides 2023 Midyear Strategic UpdateMay 24, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx's CEO Provides 2023 Midyear Strategic UpdateJune 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 24, 2023 | benzinga.comOptimizeRx's CEO Provides 2023 Midyear Strategic UpdateMay 18, 2023 | finance.yahoo.comOptimizeRx’s Karina Castagna Named One of the 2023 PM360 ELITE 100May 18, 2023 | finance.yahoo.comRevenues Tell The Story For OptimizeRx Corporation (NASDAQ:OPRX)May 12, 2023 | msn.comRecap: OptimizeRx Q1 EarningsMay 11, 2023 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from RBC CapitalMay 11, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue EstimatesMay 10, 2023 | finance.yahoo.comOptimizeRx Reports First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comInvesting in OptimizeRx (NASDAQ:OPRX) five years ago would have delivered you a 114% gainMay 3, 2023 | americanbankingnews.comOptimizeRx (OPRX) to Release Earnings on WednesdayMay 2, 2023 | finance.yahoo.comSurveyed Physicians Spell Out Preferences for Data-driven, Omnichannel Content That Delivers Clinical RelevanceApril 30, 2023 | americanbankingnews.comOptimizeRx Co. (NASDAQ:OPRX) Sees Large Drop in Short InterestApril 26, 2023 | finance.yahoo.comOptimizeRx Sets First Quarter 2023 Conference Call for May 10, 2023at 4:30 p.m. ETApril 17, 2023 | finance.yahoo.comShould You Think About Buying OptimizeRx Corporation (NASDAQ:OPRX) Now?April 4, 2023 | finance.yahoo.comOptimizeRx Releases 2023 Environmental, Social and Governance (ESG) ReportMarch 29, 2023 | finance.yahoo.comFinancial Times Ranks OptimizeRx Amongst The Americas’ Fastest Growing Companies for the Fourth Consecutive YearMarch 25, 2023 | americanbankingnews.comAnalysts Issue Forecasts for OptimizeRx Co.'s Q2 2023 Earnings (NASDAQ:OPRX)March 23, 2023 | americanbankingnews.comWilliam Blair Reiterates "Outperform" Rating for OptimizeRx (NASDAQ:OPRX)See More Headlines OPRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Company Calendar Last Earnings5/10/2023Today6/08/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees97Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+39.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,440,000.00 Net Margins-22.79% Pretax Margin-22.79% Return on Equity-9.27% Return on Assets-8.77% Debt Debt-to-Equity RatioN/A Current Ratio12.61 Quick Ratio12.61 Sales & Book Value Annual Sales$62.45 million Price / Sales4.12 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book2.04Miscellaneous Outstanding Shares17,130,000Free Float16,374,000Market Cap$257.12 million OptionableNot Optionable Beta0.98 Key ExecutivesWill FebboChief Executive Officer & DirectorEdward StelmakhChief Operations & Financial OfficerTodd InmanChief Technology OfficerMarion K. Odence-FordChief Compliance Officer & General CounselAngelo CampanoSenior Vice President & Principal-Agency ChannelsKey CompetitorsDHI GroupNYSE:DHXZeroFoxNASDAQ:ZFOXEdgioNASDAQ:EGIORimini StreetNASDAQ:RMNIGravityNASDAQ:GRVYView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 2,117 shares on 5/18/2023Ownership: 0.823%Geode Capital Management LLCBought 8,030 shares on 5/16/2023Ownership: 1.890%Arrowstreet Capital Limited PartnershipBought 24,085 shares on 5/16/2023Ownership: 0.141%Susquehanna International Group LLPBought 14,500 shares on 5/16/2023Ownership: 0.000%Balyasny Asset Management L.P.Bought 11,462 shares on 5/16/2023Ownership: 0.067%View All Insider TransactionsView All Institutional Transactions OPRX Stock - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year price targets for OptimizeRx's shares. Their OPRX share price forecasts range from $16.00 to $30.00. On average, they expect the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2023? OptimizeRx's stock was trading at $16.80 on January 1st, 2023. Since then, OPRX stock has decreased by 11.0% and is now trading at $14.96. View the best growth stocks for 2023 here. Are investors shorting OptimizeRx? OptimizeRx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 710,500 shares, a decline of 19.7% from the April 30th total of 884,500 shares. Based on an average daily trading volume, of 250,800 shares, the days-to-cover ratio is presently 2.8 days. Approximately 4.3% of the shares of the company are sold short. View OptimizeRx's Short Interest. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) posted its earnings results on Wednesday, May, 10th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The company earned $13 million during the quarter, compared to analyst estimates of $12.37 million. OptimizeRx had a negative net margin of 22.79% and a negative trailing twelve-month return on equity of 9.27%. What ETFs hold OptimizeRx's stock? ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD), Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC), What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $68.69M-, compared to the consensus revenue estimate of $68.64 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). What is OptimizeRx's stock symbol? OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX." Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.08%), First Light Asset Management LLC (5.90%), Blair William & Co. IL (4.93%), G2 Investment Partners Management LLC (3.13%), Wasatch Advisors LP (2.74%) and State Street Corp (2.47%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OptimizeRx's stock price today? One share of OPRX stock can currently be purchased for approximately $14.96. How much money does OptimizeRx make? OptimizeRx (NASDAQ:OPRX) has a market capitalization of $256.26 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. How can I contact OptimizeRx? OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529. This page (NASDAQ:OPRX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.